What They Build
Immuneel develops and commercializes cell and gene therapies, including CAR-T approaches, with a focus on making advanced cancer treatment accessible in India.
Why They Matter
Advanced therapies do not become national capability until they can be manufactured, delivered, and paid for locally. Immuneel matters because it addresses the translational and access layers, not only the science. The difficult balance is clinical rigor with affordability.
Founders
Kiran Mazumdar-Shaw, Siddhartha Mukherjee, Kush Parmar
Recent Milestones
- CAR-T therapy programs disclosed
- Clinical and manufacturing infrastructure built
- Growth funding announced